Science Current Events | Science News | Brightsurf.com
 

Easy-to-use blood thinners likely to replace Coumadin

February 07, 2012

For atrial fibrillation patients at risk for stroke

MAYWOOD, Ill. -- Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.

Unlike Coumadin, the new drugs do not require patients to come in to the clinic on a regular basis to check the dose. Nor do the drugs require extensive dietary restrictions.

First author Sarkis Morales-Vidal, MD, and colleagues describe the new drugs in a review article in the February issue of the journal Expert Reviews. Co-authors are Michael J. Schneck, MD, Murray Flaster, MD, and José Biller, MD. All are in the Department of Neurology, Stroke Program, of Loyola University Chicago Stritch School of Medicine. Biller is department chair.

The new drugs include rivaroxaban (Xarelto®), dabigatran etexilate (Pradaxa®) and apixaban (Eliquis®). They do not share the disadvantages of Coumadin, and may provide equal or superior prevention against clots, Morales and colleagues write.

Atrial fibrillation is the most common form of irregular heartbeat, and a major cause of stroke in the elderly. Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. The clots can migrate to the brain and cause strokes.

More than 3 million Americans have atrial fibrillation, and the number is increasing, due in part to the aging population.

Coumadin's generic name is warfarin. For more than 30 years, the drug had been the only anticoagulant for primary and secondary stroke prevention in patients with atrial fibrillation. But the Food and Drug Administration recently approved dabigatran and rivaroxaban to reduce the risk of stroke and blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. The FDA is considering an application to approve apixaban for the same use.

Coumadin must be carefully monitored. If the dose is too high, a patient could experience excessive bruising and be at higher risk for brain hemorrhages. If the dose is too low, the drug would be ineffective in preventing blood clots. Patients typically must come in at least once a month for a blood test to determine whether the dose needs to be adjusted. Some patients have to come in as often as twice a week.

Coumadin patients also must restrict their diets. For example, they should consume only small amounts of cranberry juice and alcohol and not eat large amounts of foods that are rich in vitamin K, such as spinach, brussels sprouts and green tea.

Disadvantages of the new medications include the limited clinical experience and lack of antidotes, the researchers wrote. The newer drugs are more expensive than Coumadin, but reduce the cost of patient monitoring and blood testing, Morales said.

Dabigatran is an effective alternative to Coumadin for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban is another promising alternative for those patients. Apixaban appears to be better than aspirin for stroke prevention in atrial fibrillation patients who are not candidates for Coumadin therapy, Morales and colleagues wrote.

The authors predict that within the next few years, the new drugs will likely replace Coumadin for long-term anticoagulation in selective patients with non-valvular atrial fibrillation.

Loyola University Health System


Related Atrial Fibrillation Current Events and Atrial Fibrillation News Articles


Study show female heart patients less likely to get blood thinning therapy
Female atrial fibrillation patients are less likely than their male counterparts to receive blood thinning therapies to prevent stroke, say University of Cincinnati College of Medicine researchers.

1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25 000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr Johannes Gho, a cardiology resident at the University Medical Center Utrecht, in Utrecht, the Netherlands.

Compared with men, women with AFib have more symptoms, worse quality of life, although higher survival
In a study published online by JAMA Cardiology, Jonathan P. Piccini, M.D., M.H.S., of Duke University Medical Center, Durham, N.C., and colleagues examined whether symptoms, quality of life, treatment, and outcomes differ between women and men with atrial fibrillation.

Older patients with atrial fibrillation at greater risk for post-op tricuspid regurgitation after mitral valve repair
Tricuspid regurgitation (TR) occurs when the heart's tricuspid valve leaks, allowing blood to flow back from the right ventricle to the right atrium.

Computer model helps physicians prescribe stroke preventing therapy
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision support tool that uses a combination of patient information and characteristics to assist physicians and patients with decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation.

Anticoagulation medications show no gender-based variations in outcomes for TAVR patients
A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.

Poor patient warfarin knowledge may increase risk of deadly side effects
Patients have poor knowledge of warfarin which may increase their risk of serious side effects, according to research presented today at EuroHeartCare 2016 by Dr Kjersti Oterhals, a nurse researcher at Haukeland University Hospital in Bergen, Norway.

Irregular heart rhythm may affect walking and strength in older adults
When older people develop atrial fibrillation -- the most common type of irregular heartbeat -- it accelerates age-related declines in walking speed, strength, balance and other aspects of physical performance, according to new research in Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.

Death of partner linked to heightened risk of irregular heartbeat for up to a year later
The death of a partner is linked to a heightened risk of developing an irregular heartbeat otherwise known as atrial fibrillation--itself a risk factor for stroke and heart failure--for up to a year afterwards, finds research published in the online journal Open Heart.

Rate, rhythm control equally effective in post-operative atrial fibrillation
In the first large randomized trial to directly compare two approaches to preventing a type of abnormal heart rhythm that is the most common complication of heart surgery, the two strategies--controlling heart rate and controlling heart rhythm--performed equally well, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.
More Atrial Fibrillation Current Events and Atrial Fibrillation News Articles

Atrial Fibrillation: Remineralize Your Heart

Atrial Fibrillation: Remineralize Your Heart


Atrial Fibrillation, an electrical disruption of the rhythm of the heart, is occurring in epidemic proportions. Medicine says there is no cure and only offers drugs and surgery for the symptoms. Because of my own heart palpitations, I searched for an effective treatment for many years. That treatment I found is based on the right kind of magnesium – one that doesn’t give you a laxative effect – well-absorbed multiple minerals and proper hydration with water and sea salt or Himalayan salt. Giving your heart the necessary minerals overcomes the electrical disruption and balances your heart rhythm. Atrial Fibrillation: Remineralize Your Heart walks you through the possible triggers for this condition and uncovers their basis in magnesium deficiency. Numerous case histories help you...

Beat Your A-Fib: The Essential Guide to Finding Your Cure: Written in everyday language for patients with Atrial Fibrillation

Beat Your A-Fib: The Essential Guide to Finding Your Cure: Written in everyday language for patients with Atrial Fibrillation
by Steve S Ryan PhD (Author), Patti J Ryan (Contributor)


Beat Your A-Fib: The Essential Guide to Finding Your Cure by Steve S. Ryan, PhD
Atrial Fibrillation (A-Fib) is the most common cardiac arrhythmia (abnormal heart rhythm) seen by physicians. Many patients suffering from Atrial Fibrillation have three strikes against them:
1. Their "quality of life" has deteriorated; they are scared or frightened.
2. Many experience side effects from the common drug therapies or simply do not want to live on medication; a cure for their A-Fib hasn't been discussed.
3. Patient information is often out-of-date, incomplete or biased toward a specific pharmaceutical or treatment; much information about new treatment options is written in the language of scientists and doctors.

The author, Dr. Steve Ryan, PhD, a former A-Fib patient,...

Atrial fibrillation e-chart: Quick reference guide

Atrial fibrillation e-chart: Quick reference guide
by HC-HealthComm


Atrial fibrillation e-chart - Quick reference guide

Atrial fibrillation. It is a tachyarrhythmia which, from a hemodynamic point of view, results in loss of coordinated, atrial contraction that is substituted for sporadic, vermicular contractions. These are called fibrillatory (f) waves and take the place of P waves. This tachyarrhythmia can be paroxysmal, acute (the episode takes place within 24 to 48 hours), or chronic. The frequency of these waves often exceeds rates of 400 beats/min. Consequently, the atrium fails to be empty and it therefore remains functionally in diastole. As regards pathogenesis of atrial fibrillation, we could find a reentry of atrial stimuli through multiple circuits that would find both refractory and excitable areas. This uncoordinated heart...

Atrial Fibrillation: What You Need to Know: A Beginner's Guide for Patients and Caregivers (Consumer Health Guides Book 1)

Atrial Fibrillation: What You Need to Know: A Beginner's Guide for Patients and Caregivers (Consumer Health Guides Book 1)
by Eternal Spiral Books, http://EternalSpiralBooks.com


++The Fifth Edition, published September 8, 2014, is now available, with updates on the latest information on atrial fibrillation, including the latest news on dabigatran, (Pradaxa), and rivaroxaban, (Xarelto), two of the blood thinning medications (anticoagulants) often prescribed for patients with atrial fibrillation, plus news on the drug digoxin, and the effectiveness of catheter ablation for AFib.

Atrial Fibrillation is a particular type of irregular heart beat which can have dangerous consequences to your health if left untreated. People with atrial fibrillation, commonly referred to as AF or AFib, are more prone to blood clots, which can lead to heart attack, stroke or even death.

Fortunately, there are a number of effective treatments available for...

Conquer Your A-Fib: How To Beat Atrial Fibrillation

Conquer Your A-Fib: How To Beat Atrial Fibrillation


Conquer your a-fib is a comprehensive guidebook for this very common arrhythmia. Containing a wealth of information and strategies for overcoming a-fib it covers:

An introduction to a-fib, what it is and how it can be treated.
Several causes of atrial fibrillation that you may not be aware of.
Dietary and chemical triggers for a-fib
Nutritional deficiencies as a potential trigger for episodes
Modifiable risk factors for a-fib which can reduce and even cure your arrhythmia.
Real life cases of people who have beaten a-fib.

Lone Atrial Fibrillation Towards a Cure

Lone Atrial Fibrillation Towards a Cure
by Hans R. Larsen (Author), MD Patrick Chambers (Preface), MD FESC Philippe Coumel (Preface)


Atrial fibrillation (AF) has been called the arrhythmia of the millennium. Millions of people suffer from lone atrial fibrillation (AF without underlying heart disease), and many don't even know they have it. There is no universally effective pharmacological treatment for lone atrial fibrillation (LAF) and relevant surgical procedures are expensive and not always successful. I experienced my first LAF episode in 1989 and fairly early on in my afib "career" I realized that if anyone was going to help me it would have to be myself. So I embarked on an intensive study to find out everything I could about LAF and to come up with effective ways of dealing with it. I perused several weighty tomes on cardiac arrhythmias, located and read over 600 peer-reviewed medical articles dealing with the...

The future of anticoagulation management in atrial fibrillation in Europe: An assessment of today's challenges with recommendations for the future

The future of anticoagulation management in atrial fibrillation in Europe: An assessment of today's challenges with recommendations for the future
by RAND Corporation


As heart arrhythmia atrial fibrillation (AF) is becoming more prevalent, we explored current and future landscapes for AF-related stroke prevention. Our recommendations target awareness, education and maintaining engagement across health services.

A Life on Hold: Crossing Paths with Atrial Fibrillation

A Life on Hold: Crossing Paths with Atrial Fibrillation
by Kevin J Kauffman (Author)


You're going about your daily routine when you suddenly feel an odd squirming in your chest. You quickly realize that it is your heart, flopping around like a fish out of water. What do you do? You probably panic! Maybe you also experience dizziness, nausea, or shortness of breath, or maybe you have no other symptoms at all. But it's still very scary because... it's your heart! This is how chronic atrial fibrillation starts for many of us, and those who develop it often have little to no prior medical history to speak of. Once the demon a-fib has set in, though, we soon find our lives redirected down a dark uncharted path, our days consumed by vain attempts to divine the elusive origins of this mysterious malady as we desperately seek a panacea that can give us back our "normal"... or...

Practical Guide to Catheter Ablation of Atrial Fibrillation

Practical Guide to Catheter Ablation of Atrial Fibrillation
by Jonathan S. Steinberg (Author), Pierre Jais (Author), Hugh Calkins (Author)


Now in its second edition, this practical guide offers clear-headed guidance to the successful application of catheter ablation for atrial fibrillation. This book concentrates on clinically-relevant information that providers can put to immediate use caring for patients. Takes a clear-headed practical approach to ablation of atrial fibrillation – long on actionable, clinically-relevant guidance, succinct and to-the-point on the theory behind the procedure Edited by three leading, internationally-known electrophysiologists with extensive experience in ablation for atrial fibrillation Written by international team of experts reflecting global best practices from centers with considerable experience in the use of catheter ablation Format designed to serve the needs of electrophysiologists...

Atrial Fibrillation Pocketcard Set

Atrial Fibrillation Pocketcard Set
by A. Bavry (Author), C. y. Choi (Author)


The Atrial Fibrillation pocketcard Set includes general information on the diagnosis and management of atrial fibrillation (AF). This includes: * Prevalence, etiology, classification, and evaluation of AF * General guidelines for rhythm and rate control methods of AF management * Information on invasive strategies for the treatment of AF * Management of AF in special circumstance including pregnancy, pulmonary disease, and acute myocardial infarction * Guidelines and flowchart for anticoagulation in AF * Guidelines for sinus rhythm maintenance in recurrent paroxysmal and persistent atrial fibrillation Antiarrhythmic drug administration information for rate control, cardioversion, and maintenance, including dosage and common adverse effects *

© 2016 BrightSurf.com